Vadodara News Flash

Soft Tissue Sarcoma Pipeline Analysis: 130+ Companies are working to improve the Treatment

 Breaking News
  • No posts were found

Soft Tissue Sarcoma Pipeline Analysis: 130+ Companies are working to improve the Treatment

November 15
00:48 2022
Soft Tissue Sarcoma Pipeline Analysis: 130+ Companies are working to improve the Treatment

DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight, 2022,” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Soft Tissue Sarcoma Pipeline Report

  • 130+ Key companies are actively engaged in the Soft Tissue Sarcoma market landscape.
  • The leading Soft Tissue Sarcoma Companies such as NanoCarrier, Philogen, Lytix Biopharma, Karyopharm Therapeutics, Genentech, Nanobiotix, Boehringer Ingelheim, Eisai, Daiichi Sankyo, Hutchison MediPharma, Merck & Co, Incyte Corporation, Pfizer, Rafael Pharmaceuticals, NewVac, Hillstream BioPharma, Taiwan Liposome Company, Shanghai Junshi Biosciences, AstraZeneca, Monopar Therapeutics, Adaptimmune, GlaxoSmithKline,  AVEO Oncology, Novartis, Kyowa Kirin, Macrogenics, Merrimack Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Bristol-Myers Squibb,  SYZ Cell Therapy, Presage Biosciences, Cebiotex, Cyteir Therapeutics, Apexigen, BioAtla, Guangdong Xiangxue Precision Medical among others.
  • Promising Soft Tissue Sarcoma Pipeline Therapies such as AL3818, L19 TNF, NBTXR3, GPX-150, LTX-315, Nivolumab, Lenvatinib, Durvalumab, Nintedanib, and others
  • The assessment part of the report embraces, in depth Soft Tissue Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Recent Breakthroughs of Soft Tissue Sarcoma Treatment Landscape

  • In December 2020, Moleculin Biotech announced that FDA granted an orphan drug designation to annamycin for soft tissue sarcoma.
  • In October 2020, Rafael Pharmaceuticals announced that the FDA has granted an Orphan Drug designation to CPI-613 (devimistat) for the treatment of soft tissue sarcoma.
  • In July 2019, Monopar Therapeutics and the Spanish Sarcoma Group announced that they have entered into a clinical collaboration agreement to conduct a Phase 2 clinical trial to evaluate Monopar’s investigational drug Camsirubicin in patients with advanced soft tissue sarcoma (ASTS).
  • In March 2019, Italian cancer startup Philogen got off an impressive $70M funding round.

Request a sample and discover the recent advances in Soft Tissue Sarcoma Treatment @ Soft Tissue Sarcoma Pipeline Outlook Report

Soft Tissue Sarcoma Overview

Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course. According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow-growing, painless mass in the affected area.

Soft Tissue Sarcoma Emerging Drugs

AL3818: Advenchen Laboratories

AL3818 is a novel small molecule dual receptor tyrosine kinase inhibitor, which shows highly selective inhibition of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR). Advenchen Laboratories, LLC is developing AL-3818 for the treatment of patients with advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), synovial sarcoma (SS), and soft-tissue sarcoma (STS). The drug is currently in the Phase III stage of development.

L19 TNF: Philogen

Onfekafusp alfa (L19 TNF) is a fully human recombinant fusion protein being developed by Philogen for the treatment of cancer, including gliomas, glioblastoma. It is a human antibody-cytokine fusion protein consisting of the non-covalent trimer of tumor necrosis factor (TNF) fused to an antibody specific to the extra-domain B of fibronectin (L19) in the single-chain variable fragment (scFv) format. The antibody-TNF fusion protein selectively localizes to tumor lesions following systemic administration. It is currently being studied in Phase III and Phase II of clinical development to treat STS patients in Europe and the United States, respectively.

NBTXR3: Nanobiotix

Hensify (NBTXR3), is a first-in-class nanoparticle radio-enhancer designed for direct injection into cancerous tumors and is engineered to increase the dose and efficacy of radiotherapy without increasing toxicity or causing damage to surrounding healthy tissues. NBTXR3 has the potential to improve radiotherapy efficacy by destroying locally advanced tumors more efficiently, improving the chance of full tumor resection. Treatment with NBTXR3 nanoparticles and radiotherapy in locally advanced STS aims to destroy tumors more efficiently, to facilitate surgery and enable complete malignant tissue extraction during surgery. Currently, it is in phase II/III stage of development.

GPX-150: Monopar Therapeutics

GPX-150, also known as camsirubicin, is a novel proprietary analog of the widely used cancer drug doxorubicin. Camsirubicin has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the toxic effects on the heart. The drug is currently being studied in the Phase II stage of development for the treatment of patients with STS.

LTX-315: Lytix Biopharma

Lytix’s product candidate LTX-315 is a first-in-class oncolytic peptide with the potential to fully personalize immunotherapy. LTX-315 is developed for the intratumoral treatment of solid tumors turning cold tumors hot. LTX-315 triggers the immune system to recognize, infiltrate and attack the cancer cells, opening up the tumor for various combination treatments, including the marketed checkpoint inhibitors.

Nivolumab: Bristol Myers Squibb

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). PD-L1 and PD-L2 ligands bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2 ligands on their surface. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient’s tumor-specific T-cell response. The clinical trials for nivolumab are currently ongoing in phase II for the treatment of patients with STS.

Lenvatinib: Merck sharp & Dohme Corp.

Lenvatinib is an orally available, multiple receptor tyrosine kinase (RTK) inhibitor with the novel binding mode that selectively inhibits the kinase activities of VEGFR-1, -2, and -3. The drug is currently being studied in Phase II in combination with pembrolizumab, a monoclonal antibody that binds to PD-1 and prevents its interaction with PD-1 and PD-2. 

Durvalumab: AstraZeneca

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune checkpoint inhibitor for cancer treatment. The expression of PD-L1 is an adaptive immune response by tumor cells, resulting in overexpression of the molecule in some cancers. Durvalumab activates the immune responses mediated by cytotoxic T-cells that attack tumor cells by binding to PD-L1, thereby inhibiting its interaction with PD-1 on T-cells. The drug is currently in Phase II clinical trial for the treatment of patients with metastatic STS.

Nintedanib: Boehringer Ingelheim

Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, colony-stimulating factor 1 receptor (CSF1R), and Fms-like tyrosine kinase-3 (FLT-3). These kinases, except for FLT-3 have been implicated in the pathogenesis of interstitial lung diseases (ILD). Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these kinases and blocks the intracellular signaling cascades, which have been demonstrated to be involved in the pathogenesis of fibrotic tissue remodeling in ILD. Nintedanib also inhibits the following nRTKs: Lck, Lyn and Src kinases. The contribution of FLT-3 and nRTK inhibition to nintedanib efficacy in ILD is unknown. Currently, it is in phase 2 stage of development to treat soft tissue sarcoma.

DelveInsight’s Soft Tissue Sarcoma Pipeline report covers around 130+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Learn more about the novel and emerging Soft Tissue Sarcoma pipeline therapies @ Soft Tissue Sarcoma Clinical Trials

Scope of the Soft Tissue Sarcoma Pipeline Report

  • Coverage- Global
  • Soft Tissue Sarcoma Therapeutics Assessment by Product Type
  • Soft Tissue Sarcoma Therapeutics Assessment by Stage and Product Type
  • Soft Tissue Sarcoma Therapeutics Assessment by Route of Administration
  • Soft Tissue Sarcoma Therapeutics Assessment by Stage and Route of Administration
  • Soft Tissue Sarcoma Therapeutics Assessment by Molecule Type
  • Soft Tissue Sarcoma Therapeutics Assessment by Stage and Molecule Type
  • Soft Tissue Sarcoma Companies- NanoCarrier, Philogen, Lytix Biopharma, Karyopharm Therapeutics, Genentech, Nanobiotix, Boehringer Ingelheim, Eisai, Daiichi Sankyo, Hutchison MediPharma, Merck & Co, Incyte Corporation, Pfizer, Rafael Pharmaceuticals, NewVac, Hillstream BioPharma, Taiwan Liposome Company, Shanghai Junshi Biosciences, AstraZeneca, Monopar Therapeutics, Adaptimmune, GlaxoSmithKline,  AVEO Oncology, Novartis, Kyowa Kirin, Macrogenics, Merrimack Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Bristol-Myers Squibb,  SYZ Cell Therapy, Presage Biosciences, Cebiotex, Cyteir Therapeutics, Apexigen, BioAtla, Guangdong Xiangxue Precision Medical among others.
  • Soft Tissue Sarcoma Pipeline Therapies such as AL3818, L19 TNF, NBTXR3, GPX-150, LTX-315, Nivolumab, Lenvatinib, Durvalumab, Nintedanib, and others

Table of Content

  1. Introduction
  2. Executive Summary
  3. Soft Tissue Sarcoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. L19-TNF: Philogen
  8. Mid Stage Products (Phase II)
  9. Durvalumab: AstraZeneca
  10. Early Stage Products (Phase I/II)
  11. TBI-1301: Takara Bio
  12. Early Stage Products (Phase I)
  13. CEB-01: Cebiotex
  14. Preclinical and Discovery Stage Products
  15. HSB-114: Hillstream BioPharma
  16. Inactive Products
  17. Soft Tissue Sarcoma Key Companies
  18. Soft Tissue Sarcoma Key Products
  19. Soft Tissue Sarcoma- Unmet Needs
  20. Soft Tissue Sarcoma- Market Drivers and Barriers
  21. Soft Tissue Sarcoma- Future Perspectives and Conclusion
  22. Soft Tissue Sarcoma Analyst Views
  23. Soft Tissue Sarcoma Key Companies
  24. Appendix

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Soft Tissue Sarcoma drugs?
  • How many Soft Tissue Sarcoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Soft Tissue Sarcoma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Soft Tissue Sarcoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Soft Tissue Sarcoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Got Queries? Get in touch with our Business Development Executive @ Soft Tissue Sarcoma Market Drivers and Barriers

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles